Single-cut gene therapy in a one-step generated rhesus monkey model of Duchenne muscular dystrophy.

IF 11.7 1区 医学 Q1 CELL BIOLOGY
Raoxian Bai, Wenting Guo, Ting Zhang, Shuaiwei Ren, Jie Liu, Puhao Xiao, Junyu Zhang, Wenjie Sun, Jiao Yang, Yue Ma, Siyu Liu, Chaoran Zhou, Shangang Li, Hong Wang, Shu Zhang, Weizhi Ji, Shiwen Wu, Yongchang Chen
{"title":"Single-cut gene therapy in a one-step generated rhesus monkey model of Duchenne muscular dystrophy.","authors":"Raoxian Bai, Wenting Guo, Ting Zhang, Shuaiwei Ren, Jie Liu, Puhao Xiao, Junyu Zhang, Wenjie Sun, Jiao Yang, Yue Ma, Siyu Liu, Chaoran Zhou, Shangang Li, Hong Wang, Shu Zhang, Weizhi Ji, Shiwen Wu, Yongchang Chen","doi":"10.1016/j.xcrm.2025.102037","DOIUrl":null,"url":null,"abstract":"<p><p>Progress in Duchenne muscular dystrophy (DMD) treatment is hindered by the lack of animal models that closely replicate human pathology and enable the evaluation of therapy efficacy and safety based on these models. To address this need, we optimize the generation of nonhuman primate DMD models, reducing the development time from 6 to 7 years to under 1 year, enabling the rapid generation of DMD monkey models. These models closely mimic human DMD pathology and motor dysfunction, making them suitable for testing gene therapies. Using these models, we develop a single-cut gene therapy strategy that can be directly applied to humans. This treatment restores dystrophin expression, improves pathological features, and enhances motor abilities in DMD monkeys, with effects lasting at least 1.5 years. In conclusion, we achieve the rapid generation of DMD monkey models and demonstrate that our gene therapy approach is effective and holds significant potential for clinical application.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102037"},"PeriodicalIF":11.7000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102037","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Progress in Duchenne muscular dystrophy (DMD) treatment is hindered by the lack of animal models that closely replicate human pathology and enable the evaluation of therapy efficacy and safety based on these models. To address this need, we optimize the generation of nonhuman primate DMD models, reducing the development time from 6 to 7 years to under 1 year, enabling the rapid generation of DMD monkey models. These models closely mimic human DMD pathology and motor dysfunction, making them suitable for testing gene therapies. Using these models, we develop a single-cut gene therapy strategy that can be directly applied to humans. This treatment restores dystrophin expression, improves pathological features, and enhances motor abilities in DMD monkeys, with effects lasting at least 1.5 years. In conclusion, we achieve the rapid generation of DMD monkey models and demonstrate that our gene therapy approach is effective and holds significant potential for clinical application.

一步生成的恒河猴杜氏肌营养不良模型的单切口基因治疗。
杜氏肌营养不良症(DMD)治疗的进展受到缺乏动物模型的阻碍,这些动物模型能够密切复制人类病理,并能够根据这些模型评估治疗的疗效和安全性。为了解决这一需求,我们优化了非人灵长类动物DMD模型的生成,将开发时间从6 - 7年缩短到1年以下,实现了DMD猴模型的快速生成。这些模型密切模仿人类DMD病理和运动功能障碍,使它们适合测试基因疗法。利用这些模型,我们开发了一种可以直接应用于人类的单切口基因治疗策略。这种治疗恢复了肌营养不良蛋白的表达,改善了DMD猴子的病理特征,并增强了运动能力,效果持续至少1.5年。总之,我们实现了DMD猴子模型的快速生成,并证明了我们的基因治疗方法是有效的,具有重要的临床应用潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell Reports Medicine
Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
15.00
自引率
1.40%
发文量
231
审稿时长
40 days
期刊介绍: Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信